Core Viewpoint - The company emphasizes its commitment to innovation and collaboration in research and development, focusing on both the quantity and quality of its R&D efforts [2] Group 1: R&D Strategy - The company is enhancing its R&D foundation and optimizing conventional drug processes to improve cost-effectiveness [2] - It is accelerating the transformation of R&D results, particularly in the fields of biological veterinary medicine and traditional Chinese veterinary medicine [2] Group 2: New Product Development - The company has obtained approval for six new veterinary drug formulations this year, including two products, chlorhexidine acetate soft capsules and enconazole solution, which fill gaps in the domestic market [2] - The approval of new products is expected to enhance the company's market competitiveness, although market acceptance for these new products will require time [2]

Group 1: Financial Performance - In the first three quarters of 2025, the company achieved revenue of 1.26 billion CNY, a year-on-year increase of 58.92% [1] - Net profit attributable to shareholders reached 188 million CNY, up 494.28% year-on-year; net profit excluding non-recurring items was 166 million CNY, a growth of 611.92% [1] - In Q3 2025, revenue was 437 million CNY, reflecting a year-on-year growth of 22.76%; net profit attributable to shareholders was 70.72 million CNY, a staggering increase of 1,575.79% [1][2] Group 2: Strategic Initiatives - The company focuses on a dual strategy of vertical integration in raw material pharmaceuticals and horizontal expansion into pet, poultry, ruminant, and aquaculture sectors [1] - Continuous investment in R&D has enriched the product matrix and reduced production costs, contributing to record operational performance [3] Group 3: Product Development - The company has obtained 6 new veterinary drugs this year, including two products that fill domestic market gaps [3] - New products are expected to enhance market competitiveness, although their promotion requires gradual market acceptance [3] Group 4: Market Expansion - The company is actively pursuing an "outbound" strategy, with a production base in Vietnam now operational and 63 production approvals obtained [4] - A sales service company has been established in Indonesia to explore new overseas markets [4] Group 5: Accounts Receivable Management - The company maintains a robust accounts receivable management system, ensuring careful evaluation of customer credit situations [5] - Current credit policies remain unchanged, and customer payment collection is normal [5] Group 6: Pet Business Development - The company has increased investment in pet drug R&D and market channel development, utilizing both online and offline sales strategies [6][7] - The pet segment has shown strong sales growth, with new products like the Enrofloxacin solution addressing market needs [7]

Core Viewpoint - The approval of "Chlorhexidine Acetate Soft Capsules" as a new veterinary drug by the Ministry of Agriculture and Rural Affairs of the People's Republic of China marks a significant development for the company and the veterinary pharmaceutical industry [1] Company Summary - Wuhan Huisheng Biotechnology Co., Ltd. and its subsidiaries jointly applied for the new veterinary drug registration [1] - The new veterinary drug registration certificate was issued on August 26, 2025, under the announcement No. 943 by the Ministry of Agriculture and Rural Affairs [1] Industry Summary - The approved drug, Chlorhexidine Acetate Soft Capsules, is intended for use as a disinfectant and antiseptic [1] - It is specifically used to treat vaginal inflammation in pigs caused by sensitive bacteria, prevent postpartum uterine infections, and address endometritis caused by sensitive bacteria [1]

Core Viewpoint - The approval of "Chlorhexidine Acetate Soft Capsules" as a new veterinary drug by the Ministry of Agriculture and Rural Affairs of the People's Republic of China marks a significant development for the company and the veterinary pharmaceutical industry [1]. Company Summary - Wuhan Huisheng Biotechnology Co., Ltd. and its subsidiaries have jointly applied for the new veterinary drug, which has now received official registration [1]. - The new veterinary drug is aimed at treating conditions in pigs, specifically vaginitis caused by sensitive bacteria, and preventing postpartum uterine infections and endometritis [1]. Industry Summary - The approval of new veterinary drugs like Chlorhexidine Acetate Soft Capsules reflects ongoing advancements in the veterinary pharmaceutical sector, enhancing treatment options for livestock [1]. - The regulatory framework under which the drug was approved includes the "Veterinary Drug Management Regulations" and the "Veterinary Drug Registration Measures," indicating a structured approach to drug approval in the industry [1].